Alteration of neurotensin receptors in MPTP-treated mice
- PMID: 10477079
- DOI: 10.1016/s0196-9781(99)00065-0
Alteration of neurotensin receptors in MPTP-treated mice
Abstract
We examined the sequential changes in neurotensin receptors in the striatum and substantia nigra of mouse brains lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by receptor autoradiography, in comparison with the alterations in dopamine uptake sites. The mice received four intraperitoneal injections of MPTP (10 mg/kg) at 1-h intervals and then the brains were analyzed at 6 h and 1, 3, 7, and 21 days after the treatments. [3H]Neurotensin and [3H]mazindol were used to label neurotensin receptors and dopamine uptake sites, respectively. [3H]Neurotensin binding was significantly decreased in the striatum from 6 h to 21 days after MPTP treatment. In the substantia nigra, pars reticulata also showed a significant decrease in [3H]neurotensin binding from 3 to 21 days post-MPTP treatment. However, no significant change in [3H]neurotensin binding was observed in the pars compacta even after 21 days. On the other hand, [3H]mazindol binding was markedly decreased in the striatum and substantia nigra from 6 h to 21 days after MPTP treatment. These results indicate that neurotoxin MPTP can produce a severe decrease in neurotensin receptors and dopamine uptake sites in the striatum and substantia nigra of mice. Thus, our findings provide evidence that the dysfunction in neurotensin receptors may be involved in the degenerative processes causing Parkinson's disease.
Similar articles
-
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.Eur J Pharmacol. 1995 Apr 24;277(2-3):235-41. doi: 10.1016/0014-2999(95)00086-z. Eur J Pharmacol. 1995. PMID: 7493614
-
Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.Brain Res. 1999 Apr 10;824(2):224-31. doi: 10.1016/s0006-8993(99)01209-3. Brain Res. 1999. PMID: 10196452
-
Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.Eur J Pharm Sci. 2001 Jan;12(3):231-8. doi: 10.1016/s0928-0987(00)00170-6. Eur J Pharm Sci. 2001. PMID: 11113642
-
Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.Neurochirurgie. 1991;37(6):377-82. Neurochirurgie. 1991. PMID: 1780015 Review.
-
Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.Mol Chem Neuropathol. 1989 Jun;10(3):171-83. doi: 10.1007/BF03159727. Mol Chem Neuropathol. 1989. PMID: 2669769 Review. No abstract available.
Cited by
-
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.Neurosci Bull. 2010 Oct;26(5):345-54. doi: 10.1007/s12264-010-0518-y. Neurosci Bull. 2010. PMID: 20882060 Free PMC article.
-
The role of neurotensin in central nervous system pathophysiology: what is the evidence?J Psychiatry Neurosci. 2006 Jul;31(4):229-45. J Psychiatry Neurosci. 2006. PMID: 16862241 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous